Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types
Dysfunctional homologous recombination DNA repair (HRR), frequently due to BRCA mutations, is a determinant of sensitivity to platinum chemotherapy and poly(ADP-ribose) polymerase inhibitors (PARPi). In cultures of ovarian cancer cells, we have previously shown that HRR function, based upon RAD51 fo...
Main Authors: | Lucy Gentles, Bojidar Goranov, Elizabeth Matheson, Ashleigh Herriott, Angelika Kaufmann, Sally Hall, Asima Mukhopadhyay, Yvette Drew, Nicola J. Curtin, Rachel L O’Donnell |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/11/3/354 |
Similar Items
-
ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms
by: Harriet E. D. Southgate, et al.
Published: (2020-04-01) -
Approches protéomiques appliquées à l'étude de la poly(adp-ribosyl)ation
by: Gagné, Jean-Philippe
Published: (2009) -
PARP inhibitors in cancer therapy: Magic bullets but moving targets
by: Girish M. Shah, et al.
Published: (2013-11-01) -
Strategies for structural studies of poly(ADP-ribose) glycohydrolase: Towards the validation of a novel therapeutic target
by: Botta, Davide
Published: (2010) -
Targeting <i>BRCA</i> Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?
by: Emanuel Nicolas, et al.
Published: (2018-12-01)